You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,498,486


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,498,486
Title:Method for controlled release oral dosage of a vitamin D compound
Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s): Bishop; Charles W. (Miami Beach, FL), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy A. (Mississauga, CA), White; Jay A. (Newmarket, CA), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA), Crawford; Keith H. (Lone Tree, CO)
Assignee: OPKO RENAL, LLC (Miami, FL) OPKO IRELAND GLOBAL HOLDINGS, LTD. (Grand Cayman, KY)
Application Number:15/231,357
Patent Claims:1. A method of treating secondary hyperparathyroidism in a human patient having Chronic Kidney Disease (CKD), comprising administering to the human patient having CKD an effective amount of a sustained release, oral dosage form of 25-hydroxyvitamin D to treat the secondary hyperparathyroidism and reduce the patient's serum parathyroid hormone level, wherein the administration avoids transient increases in blood levels of 25-hydroxyvitamin D of greater than 3 ng/mL following a unit dose.

2. The method of claim 1, comprising administering 30 .mu.g or 60 .mu.g of 25-hydroxyvitamin D.sub.3.

3. The method of claim 1, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier.

4. The method of claim 3, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier, a lipoidic agent, and an oily vehicle for the 25-hydroxyvitamin D compound.

5. The method of claim 1, comprising administering said oral dosage on a schedule of once per day.

6. The method of claim 1, wherein the patient has CKD Stage 5.

7. The method of claim 1, wherein the patient has CKD Stage 1 or 2.

8. The method of claim 1, wherein the patient has CKD Stage 3 or 4.

9. A method of treating secondary hyperparathyroidism in a human patient having Chronic Kidney Disease (CKD), comprising administering to the human patient having CKD an effective amount of a sustained release, oral dosage form of 25-hydroxyvitamin D to treat the secondary hyperparathyroidism and reduce the patient's serum parathyroid hormone level, wherein the sustained release is effected over a period of at least four hours.

10. The method of claim 9, comprising administering 30 .mu.g or 60 .mu.g of 25-hydroxyvitamin D.sub.3.

11. The method of claim 9, wherein the administration avoids transient increases in blood levels of 25-hydroxyvitamin D of greater than 3 ng/mL following a unit dose.

12. The method of claim 9, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier.

13. The method of claim 9, comprising administering said oral dosage on a schedule of once per day.

14. The method of claim 9, wherein the patient has CKD Stage 5.

15. The method of claim 9, wherein the patient has CKD Stage 1 or 2.

16. The method of claim 9, wherein the patient has CKD Stage 3 or 4.

17. A method of treating secondary hyperparathyroidism in a human patient having Chronic Kidney Disease (CKD), comprising administering to the human patient having CKD an effective amount of a sustained release, oral dosage form of 25-hydroxyvitamin D to treat the secondary hyperparathyroidism and reduce the patient's serum parathyroid hormone level, such that (a) the ratio of the maximum serum concentration within 24 hours after administration of the vitamin D compound to the concentration 24 hours after administration (Cmax.sub.24hr/C.sub.24hr) is reduced as compared to an equivalent amount of the vitamin D compound administered by an immediate-release, oral dosage form and/or (b) the time for the plasma concentration of the vitamin D compound to reach its maximum in a dose interval following administration (Tmax) is increased as compared to Tmax for an equivalent amount of the vitamin D compound administered by an equivalent immediate-release, oral dosage form, wherein the vitamin D compound comprises 25-hydroxyvitamin D.sub.3.

18. The method of claim 17, comprising administering 30 .mu.g or 60 .mu.g of 25-hydroxyvitamin D.sub.3.

19. The method of claim 17, wherein the administration avoids transient increases in blood levels of 25-hydroxyvitamin D of greater than 3 ng/mL following a unit dose.

20. The method of claim 17, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier.

21. The method of claim 17, comprising administering said oral dosage on a schedule of once per day.

22. The method of claim 17, wherein the patient has CKD Stage 5.

23. The method of claim 17, wherein the patient has CKD Stage 1 or 2.

24. The method of claim 17, wherein the patient has CKD Stage 3 or 4.

25. A method of treating a disease or condition, comprising administering to a human patient 30 .mu.g or 60 .mu.g of an extended release, oral dosage form of 25-hydroxyvitamin D.sub.3 once daily, wherein the disease or condition is secondary hyperparathyroidism in an adult human patient having Chronic Kidney Disease (CKD) Stage 3 or 4 and serum total 25-hydroxyvitamin D levels less than 30 ng/mL.

26. The method of claim 25, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier.

27. The method of claim 26, wherein the sustained release, oral dosage form of 25-hydroxyvitamin D comprises a waxy controlled release carrier, a lipoidic agent, and an oily vehicle for the 25-hydroxyvitamin D compound.

28. The method of claim 25, wherein the patient has CKD Stage 5.

29. The method of claim 25, wherein the patient has CKD Stage 1 or 2.

30. The method of claim 25, wherein the patient has CKD Stage 3 or 4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.